Home » Newsletters » BioWorld

BioWorld

Aug. 1, 1995

View Archived Issues

CEPHALON'S JAPAN PARTNER TO MAKE $11M EQUITY INVESTMENT

RH PHARMACEUTICALS, APOTEX TAKING OVER CANGENE

AMYLIN BEGINS BATTERY OF PHASE III STUDIES FOR DIABETES

LIPOSOME CO. GETS $15M INVESTMENT FROM WISCONSIN INVESTMENT BOARD

OTHER NEWS TO NOTE

TURNING UP HEAT ON ROUNDWORMS ADDS WEEKS TO THEIR LIFE-SPAN

WARNER-LAMBERT TO PAY BIOCHEM PHARMA $30M FOR THROMBIN INHIBITOR

SCHERING-PLOUGH LICENSES VIRAZOLE FOR HEPATITIS C COMBINATION TRIALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 26, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026